|
Vaxart, Inc. (VXRT) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Vaxart, Inc. (VXRT) Bundle
Entdecken Sie den wahren Wert von Vaxart, Inc. (VXRT) mit unserem fortschrittlichen DCF -Taschenrechner! Passen Sie die wichtigsten Annahmen an, erkunden Sie verschiedene Szenarien und bewerten Sie, wie sich unterschiedliche Faktoren auswirken, wie sich die Bewertung von Vaxart, Inc. (VXRT) auswirkt - alles innerhalb einer einzelnen Excel -Vorlage.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.9 | 4.0 | .9 | .1 | 7.4 | 5.1 | 3.5 | 2.4 | 1.7 | 1.1 |
| Revenue Growth, % | 0 | -58.97 | -77.95 | -88 | 6796.26 | -31.23 | -31.23 | -31.23 | -31.23 | -31.23 |
| EBITDA | -12.2 | -28.3 | -66.5 | -103.1 | -72.1 | -5.1 | -3.5 | -2.4 | -1.7 | -1.1 |
| EBITDA, % | -123.41 | -698.52 | -7449.66 | -96372.9 | -977.54 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 3.6 | 1.8 | 2.4 | 3.3 | 8.6 | 3.9 | 2.7 | 1.8 | 1.3 | .9 |
| Depreciation, % | 36.46 | 45.63 | 272.65 | 3053.27 | 116.87 | 76.42 | 76.42 | 76.42 | 76.42 | 76.42 |
| EBIT | -15.8 | -30.1 | -68.9 | -106.4 | -80.8 | -5.1 | -3.5 | -2.4 | -1.7 | -1.1 |
| EBIT, % | -159.88 | -744.14 | -7722.31 | -99426.17 | -1094.42 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 13.5 | 126.9 | 166.5 | 93.7 | 39.7 | 5.1 | 3.5 | 2.4 | 1.7 | 1.1 |
| Total Cash, percent | .0 | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 3.6 | .3 | .1 | .0 | 3.0 | 1.1 | .8 | .5 | .4 | .3 |
| Account Receivables, % | 36.7 | 8.26 | 7.96 | 18.69 | 40.76 | 22.47 | 22.47 | 22.47 | 22.47 | 22.47 |
| Inventories | .0 | .0 | .0 | 2.0 | .0 | 1.0 | .7 | .5 | .3 | .2 |
| Inventories, % | 0.000010139931 | 0 | 0.000112107623 | 1869.16 | 0 | 20 | 20 | 20 | 20 | 20 |
| Accounts Payable | .9 | 2.1 | 3.9 | 5.5 | 1.6 | 2.9 | 2.0 | 1.4 | .9 | .6 |
| Accounts Payable, % | 8.64 | 52.72 | 434.08 | 5153.27 | 21.47 | 56.56 | 56.56 | 56.56 | 56.56 | 56.56 |
| Capital Expenditure | -.9 | -1.2 | -5.2 | -9.6 | -1.9 | -2.7 | -1.8 | -1.3 | -.9 | -.6 |
| Capital Expenditure, % | -8.62 | -30.23 | -578.14 | -8972.9 | -25.36 | -52.84 | -52.84 | -52.84 | -52.84 | -52.84 |
| Tax Rate, % | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 |
| EBITAT | -16.2 | -30.3 | -69.0 | -106.5 | -81.0 | -5.1 | -3.5 | -2.4 | -1.7 | -1.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -16.2 | -25.1 | -69.7 | -113.1 | -79.2 | -1.7 | -2.9 | -2.0 | -1.4 | -.9 |
| WACC, % | 7.24 | 7.24 | 7.24 | 7.24 | 7.24 | 7.24 | 7.24 | 7.24 | 7.24 | 7.24 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -7.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -18 | |||||||||
| Present Terminal Value | -13 | |||||||||
| Enterprise Value | -20 | |||||||||
| Net Debt | -8 | |||||||||
| Equity Value | -12 | |||||||||
| Diluted Shares Outstanding, MM | 145 | |||||||||
| Equity Value Per Share | -0.08 |
What You Will Get
- Real VXRT Financial Data: Pre-filled with Vaxart, Inc.’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Vaxart, Inc.’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Vaxart, Inc.'s historical financial reports and pre-filled projections.
- Customizable Parameters: Adjust inputs like WACC, tax rates, revenue growth, and EBITDA margins.
- Real-Time Calculations: View Vaxart, Inc.'s intrinsic value update instantly.
- Intuitive Visualizations: Dashboard graphs present valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file for Vaxart, Inc. (VXRT).
- Step 2: Review Vaxart’s pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose Vaxart, Inc. (VXRT) Calculator?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Vaxart, Inc. (VXRT).
- Customizable Inputs: Modify the highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes Vaxart's intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on Vaxart, Inc. (VXRT).
Who Should Use This Product?
- Investors: Evaluate Vaxart, Inc. (VXRT) for informed buying or selling decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess future projections for Vaxart.
- Startup Founders: Understand the valuation strategies of biotech companies like Vaxart, Inc. (VXRT).
- Consultants: Create detailed valuation reports for clients focusing on Vaxart, Inc. (VXRT).
- Students and Educators: Utilize real-time data from Vaxart, Inc. (VXRT) to teach and practice valuation skills.
What the Vaxart Template Contains
- Preloaded VXRT Data: Historical and projected financial data, including revenue, net income, and research and development expenses.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.